TD to Expand its U.S. Investment Banking Business and Capabilities with Acquisition of Cowen Inc. Click here for the Press Release

$64.75 Million

Jounce Therapeutics

Follow-on Offering

Lead Left Bookrunner, March 2021

Jounce Therapeutics, Inc. (“Jounce”) is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS.